表紙:代謝治療薬の世界市場規模調査&予測、薬剤タイプ別、適応症別、地域別分析、2023-2030年
市場調査レポート
商品コード
1314940

代謝治療薬の世界市場規模調査&予測、薬剤タイプ別、適応症別、地域別分析、2023-2030年

Global Metabolism Drugs Market Size study & Forecast, by Drug Type by Indication and Regional Analysis, 2023-2030

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
代謝治療薬の世界市場規模調査&予測、薬剤タイプ別、適応症別、地域別分析、2023-2030年
出版日: 2023年07月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の代謝治療薬市場は、2022年に約161億米ドルと評価され、予測期間2023年から2030年にかけて6.50%以上の成長率で成長すると予測されています。

代謝治療薬とは、身体の代謝プロセスを特に標的とし、影響を及ぼす薬物や治療法を指します。代謝には、食物や栄養素をエネルギーに変換し、老廃物を分解・排出するために細胞内で起こる化学反応やプロセスが含まれます。代謝治療薬は、望ましい治療効果を得るために、特定の代謝経路を刺激または阻害するように設計されています。これらの薬剤は、代謝の調節や強化、代謝障害に関連する状態の管理、体重減少の促進、特定の代謝機能不全への対処などに使用されます。代謝治療薬は、身体の代謝機能を調節する際の安全性と有効性を確保するため、厳格な研究と試験を経て開発されます。さらに、慢性疾患の有病率の増加と老年人口の増加が市場促進要因になると予想されます。さらに、製薬業界の成長と高度なヘルスケア治療を目的とした医療ツーリズムの増加が、予測期間2023-2030年の市場空間を活性化させる。

多様な集団に影響を及ぼす非感染性疾患(NCDs)の流行は、代謝治療薬市場に大きな成長機会をもたらしています。2022年の世界保健機関(WHO)によると、NCDは様々な年齢層、地域、国の個人に影響を与え、NCDに関連した1700万人の早期死亡が70歳未満で発生しています。特に懸念されるのは、このような早期死亡の86%が中低所得国で起こっていることです。不健康な食生活、運動不足、タバコ、過度のアルコール摂取などの危険因子は、様々な年齢層の人々をこれらの疾患にかかりやすくしています。メタボリックシンドローム治療薬は、このような危険因子に対処する上で重要な役割を果たすとともに、NCDsの予防、管理、治療に貢献し、世界中の人々に恩恵をもたらします。世界保健機関(WHO)によると、2020年には60歳以上の人口が10億人から14億人に増加し、世界全体で21億人に達すると予想されています。さらに、60歳以上の人口は2020年から2050年の間に3倍に増加し、約4億2600万人に達すると予想されています。しかし、副作用や安全性への懸念、高い開発コストが市場開拓の妨げになる可能性があります。

メタボリズム治療薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、代謝治療薬市場において最大の市場シェアを持つ支配的な地域です。第一に、この地域は先進的な研究開発能力を持つ強固な製薬産業を誇り、革新的な代謝治療薬の生産につながっています。第二に、北米は代謝異常の影響を受ける人口が多く、効果的な治療薬に対する市場の需要が大きいです。その他の特典として、この地域は高度な医療施設や有利な償還政策を含む確立されたヘルスケアインフラの恩恵を受けており、代謝治療薬へのアクセスが広く確保されています。最後に、代謝性疾患に特化した主要な市場プレーヤーや研究機関の存在が、代謝性医薬品市場における北米のリーダーとしての地位をより強固なものにしています。アジア太平洋地域は、人口の増加と拡大、ヘルスケアインフラの改善、可処分所得の増加、メタボリックヘルスに対する意識の高まり、ヘルスケアの進歩を促進する政府の取り組みなどの要因により、メタボリック医薬品市場において最も急成長することが予想されます。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界市場・セグメント別市場推計・予測、2020-2030年
  • 主要動向
  • 調査手法
  • 調査前提

第2章 世界の代謝治療薬市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界の代謝治療薬市場力学

  • 代謝治療薬市場のインパクト分析(2020-2030年)
    • 市場促進要因
      • 慢性疾患の増加
      • 老年人口の増加
    • 市場の課題
      • 代謝治療薬の高コスト
    • 市場機会
      • 医薬品産業の成長
      • 医療ツーリズムの増加

第4章 代謝治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治的
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 代謝治療薬の世界市場:薬物タイプ別

  • 市場スナップショット
  • 代謝治療薬の世界市場:薬物タイプ別、実績 - ポテンシャル分析
  • 代謝治療薬の世界市場、薬物タイプ別推定・予測2020~2030年
  • 代謝治療薬市場、サブセグメント別分析
    • 抗糖尿病薬
    • 脂質低下薬
    • 抗肥満薬
    • 甲状腺ホルモン薬
    • その他

第6章 代謝治療薬の世界市場:適応症別

  • 市場スナップショット
  • 代謝治療薬の世界市場:適応症別、実績 - ポテンシャル分析
  • 代謝治療薬の世界市場:適応症別推定・予測2020-2030年
  • 代謝治療薬市場、サブセグメント分析
    • 糖尿病
    • 高脂血症
    • 肥満症
    • 甲状腺機能低下症

第7章 代謝治療薬の世界市場:地域別分析

  • 主要国
  • 主な新興国
  • 代謝治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤タイプの推定・予測、2020-2030年
      • 適応症の推定・予測、2020-2030年
    • カナダ
  • 欧州代謝治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋代謝治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ代謝治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第8章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Merck Sharp & Dohme LLC
      • 主要情報
      • 概要
      • 財務(データの入手可能性によります)
      • 製品概要
      • 最近の動向
    • Novartis AG
    • Amicus Therapeutics Inc.
    • AstraZeneca PLC.
    • Boehringer Ingelheim International GmbH
    • Takeda Pharmaceutical Company Limited
    • Sanofi S.A.
    • GlaxoSmithKline PLC.
    • Horizon Therapeutics PLC
    • BioMarin Pharmaceutical Inc.

第9章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提
図表

LIST OF TABLES

  • TABLE 1. Global Metabolism Drug Market, report scope
  • TABLE 2. Global Metabolism Drug Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Metabolism Drug Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
  • TABLE 4. Global Metabolism Drug Market estimates & forecasts by Indication 2020-2030 (USD Billion)
  • TABLE 5. Global Metabolism Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Metabolism Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Metabolism Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Metabolism Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Metabolism Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Metabolism Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Metabolism Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Metabolism Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Metabolism Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Metabolism Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. U.S. Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. Canada Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. Canada Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. UK Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22. UK Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Germany Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25. Germany Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. France Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28. France Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Italy Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31. Italy Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Spain Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34. Spain Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. RoE Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37. RoE Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. China Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40. China Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. India Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43. India Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. Japan Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46. Japan Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. South Korea Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49. South Korea Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Australia Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52. Australia Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Brazil Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58. Brazil Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Mexico Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61. Mexico Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. RoLA Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64. RoLA Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Saudi Arabia Metabolism Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67. South Africa Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. RoMEA Metabolism Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Metabolism Drug Market
  • TABLE 70. List of primary sources, used in the study of global Metabolism Drug Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Metabolism Drug Market, research methodology
  • FIG 2. Global Metabolism Drug Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Metabolism Drug Market, key trends 2022
  • FIG 5. Global Metabolism Drug Market, growth prospects 2023-2030
  • FIG 6. Global Metabolism Drug Market, porters 5 force model
  • FIG 7. Global Metabolism Drug Market, pest analysis
  • FIG 8. Global Metabolism Drug Market, value chain analysis
  • FIG 9. Global Metabolism Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Metabolism Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Metabolism Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Metabolism Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Metabolism Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Metabolism Drug Market, regional snapshot 2020 & 2030
  • FIG 15. North America Metabolism Drug Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Metabolism Drug Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Metabolism Drug Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Metabolism Drug Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Metabolism Drug Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Metabolism Drugs Market is valued approximately at USD 16.10 billion in 2022 and is anticipated to grow with a growth rate of more than 6.50% over the forecast period 2023-2030. A metabolism drug refers to a medication or treatment that specifically targets and affects the body's metabolic processes. Metabolism encompasses the chemical reactions and processes that occur within cells to convert food and nutrients into energy, as well as the breakdown and elimination of waste products. A metabolism drug is designed to either stimulate or inhibit certain metabolic pathways in order to achieve desired therapeutic outcomes. These drugs can be used to regulate or enhance metabolism, manage conditions related to metabolic disorders, promote weight loss, or address specific metabolic dysfunctions. Metabolism drugs are developed through rigorous research and testing to ensure safety and efficacy in modulating the body's metabolic functions. Moreover, increasing prevalence of chronic disease and rising geriatric population are anticipated market drivers. Furthermore, growing pharmaceuticals industry and increasing medical tourism for advanced healthcare treatment fuel the market space during the forecast period 2023-2030.

The prevalence of noncommunicable diseases (NCDs) affecting diverse populations presents a significant growth opportunity for the metabolism drug market. According to the World Health Organization (WHO) in 2022, NCDs impact individuals of various age groups, regions, and nations, with 17 million premature NCD-related deaths occurring before the age of 70. Particularly concerning is that 86% of these premature deaths transpire in low and middle-income countries. Risk factors such as unhealthy diets, physical inactivity, tobacco exposure, and excessive alcohol consumption make people across different age groups susceptible to these conditions. Metabolism drugs play a crucial role in addressing these risk factors and can contribute to the prevention, management, and treatment of NCDs, benefiting individuals globally. According to the World Health Organization (WHO) in 2020, the population of individuals aged 60 years and above increased from 1 billion to 1.4 billion, with expectations of reaching a staggering 2.1 billion globally. Additionally, there is an anticipation of the number of individuals aged 60 years or older tripling between 2020 and 2050, accounting for approximately 426 million individuals. However, side effects & safety concerns and high cost of development may hamper market growth.

The key regions considered for the Global Metabolism Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the dominant region in the Metabolism Drug Market with largest market share. Firstly, the region boasts a robust pharmaceutical industry with advanced research and development capabilities, leading to the production of innovative metabolism drugs. Secondly, North America has a significant population affected by metabolic disorders, creating a substantial market demand for effective treatments. Additionally, the region benefits from well-established healthcare infrastructure, including advanced medical facilities and favorable reimbursement policies, ensuring widespread access to metabolism drugs. Lastly, the presence of key market players and research institutions focused on metabolic disorders further solidifies North America's position as a leader in the metabolism drug market. Asia Pacific is expected to be the fastest growing market for metabolism drugs due to factors such as a large and expanding population, improving healthcare infrastructure, rising disposable incomes, growing awareness of metabolic health, and government initiatives promoting healthcare advancement.

Major market player included in this report are:

  • Merck Sharp & Dohme LLC
  • Novartis AG
  • Amicus Therapeutics Inc.
  • AstraZeneca PLC.
  • Boehringer Ingelheim International GmbH
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • GlaxoSmithKline PLC.
  • Horizon Therapeutics PLC
  • BioMarin Pharmaceutical Inc.

Recent Developments in the Market:

  • In January 2023, Researchers from the University of Galway, affiliated with APC Microbiome Ireland, have created a new resource of digital microbes specifically focused on drug metabolism. This collection of over 7,000 digital microorganisms allows for computer simulations and predictions of metabolic changes in individuals, offering insights into how pharmacological treatments may function and how patients might respond. The tool holds significant potential for studying diseases such as inflammatory bowel, Parkinson's, and colorectal cancer, marking a significant milestone in understanding the human response to medical therapy.
  • In March 2023, A team of researchers from the Indian Institute of Science Education and Research in Bhopal has developed an artificial intelligence (AI) system that can predict how the gut flora would metabolize various foods and medications. This web-based application focuses on the specific bacterial enzymes, processes, and bacteria involved in the digestion and absorption of food in the human gut. The system holds promise in understanding the complex interactions between gut flora and metabolism.

Global Metabolism Drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimatio: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Type, Indication, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

  • Antidiabetic Drugs
  • Lipid Lowering Drugs
  • Anti-Obesity Drugs
  • Thyroid Hormone Drugs
  • Others

By Indication:

  • Diabetes
  • Hyperlipidaemia
  • Obesity
  • Hypothyroidism

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Metabolism Drug Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Metabolism Drug Market, by Drug Type, 2020-2030 (USD Billion)
    • 1.2.3. Metabolism Drug Market, by Indication, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Metabolism Drug Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Metabolism Drug Market Dynamics

  • 3.1. Metabolism Drug Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of Chronic Disease
      • 3.1.1.2. Rising geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of metabolism drug
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing pharmaceuticals industry
      • 3.1.3.2. Increasing medical tourism

Chapter 4. Global Metabolism Drug Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Metabolism Drug Market, by Drug Type

  • 5.1. Market Snapshot
  • 5.2. Global Metabolism Drug Market by Drug Type, Performance - Potential Analysis
  • 5.3. Global Metabolism Drug Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
  • 5.4. Metabolism Drug Market, Sub Segment Analysis
    • 5.4.1. Antidiabetic Drugs
    • 5.4.2. Lipid Lowering Drugs
    • 5.4.3. Anti-Obesity Drugs
    • 5.4.4. Thyroid Hormone Drugs
    • 5.4.5. Others

Chapter 6. Global Metabolism Drug Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global Metabolism Drug Market by Indication, Performance - Potential Analysis
  • 6.3. Global Metabolism Drug Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
  • 6.4. Metabolism Drug Market, Sub Segment Analysis
    • 6.4.1. Diabetes
    • 6.4.2. Hyperlipidaemia
    • 6.4.3. Obesity
    • 6.4.4. Hypothyroidism

Chapter 7. Global Metabolism Drug Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Metabolism Drug Market, Regional Market Snapshot
  • 7.4. North America Metabolism Drug Market
    • 7.4.1. U.S. Metabolism Drug Market
      • 7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Metabolism Drug Market
  • 7.5. Europe Metabolism Drug Market Snapshot
    • 7.5.1. U.K. Metabolism Drug Market
    • 7.5.2. Germany Metabolism Drug Market
    • 7.5.3. France Metabolism Drug Market
    • 7.5.4. Spain Metabolism Drug Market
    • 7.5.5. Italy Metabolism Drug Market
    • 7.5.6. Rest of Europe Metabolism Drug Market
  • 7.6. Asia-Pacific Metabolism Drug Market Snapshot
    • 7.6.1. China Metabolism Drug Market
    • 7.6.2. India Metabolism Drug Market
    • 7.6.3. Japan Metabolism Drug Market
    • 7.6.4. Australia Metabolism Drug Market
    • 7.6.5. South Korea Metabolism Drug Market
    • 7.6.6. Rest of Asia Pacific Metabolism Drug Market
  • 7.7. Latin America Metabolism Drug Market Snapshot
    • 7.7.1. Brazil Metabolism Drug Market
    • 7.7.2. Mexico Metabolism Drug Market
  • 7.8. Middle East & Africa Metabolism Drug Market
    • 7.8.1. Saudi Arabia Metabolism Drug Market
    • 7.8.2. South Africa Metabolism Drug Market
    • 7.8.3. Rest of Middle East & Africa Metabolism Drug Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Merck Sharp & Dohme LLC
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Novartis AG
    • 8.3.3. Amicus Therapeutics Inc.
    • 8.3.4. AstraZeneca PLC.
    • 8.3.5. Boehringer Ingelheim International GmbH
    • 8.3.6. Takeda Pharmaceutical Company Limited
    • 8.3.7. Sanofi S.A.
    • 8.3.8. GlaxoSmithKline PLC.
    • 8.3.9. Horizon Therapeutics PLC
    • 8.3.10. BioMarin Pharmaceutical Inc.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption